Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs 10X Genomics Inc — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $69.36, while 10X Genomics Inc trades at $57.98 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| SLVO | TXG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $107.41 | $58.57 |
52-Week Low | $61.81 | $11.34 |
Market Cap | — | $7.61B |
Enterprise Value | — | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLVO trades at $69.34, up 0.43% with mixed technical signals showing a bullish moving average trend but bearish oscillators including an overbought RSI. The stock recently crossed below its 50-day moving average of $73.20, indicating potential near-term pressure. Recent news highlights silver price volatility and technical breakdowns affecting this silver-focused ETN.
Outlook remains cautious with technical indicators suggesting overbought conditions while silver market volatility poses headwinds. Investment opportunity exists for traders capitalizing on silver price swings, but risks include commodity price sensitivity and technical resistance levels. The stock faces pressure from declining silver prices and dollar strength.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
